Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia

被引:34
|
作者
Sakabe, K [1 ]
Fukuda, N [1 ]
Wakayama, K [1 ]
Nada, T [1 ]
Shinohara, H [1 ]
Tamura, Y [1 ]
机构
[1] Natl Zentsuji Hosp, Dept Cardiol & Clin Res, Kagawa 7658507, Japan
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 04期
关键词
D O I
10.1016/j.amjcard.2004.04.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this prospective study, we found beneficial short-term effects from atorvastatin therapy, including effects on low-density lipoprotein subfractions and remnant-like lipoprotein particle cholesterol, antioxidant effects, and alterations in endothelial function that may be important in early benefit from statin therapy; some effects would support much earlier benefit than previously reported. We also found long-term effects of atorvastatin, including decreased plasminogen activator inhibitor type-1 and additional significant alterations in low-density lipoprotein subfractions and endothelial function, supporting benefits from continuous long-term atorvastatin therapy beyond early reversal of hypercholesterolemia. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码:497 / 500
页数:4
相关论文
共 50 条
  • [31] Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients
    Catapano, Alberico L.
    Davidson, Michael H.
    Ballantyne, Christie M.
    Brady, William E.
    Gazzara, Russell A.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (10) : 2041 - 2053
  • [32] Optimal use of lipid-altering therapy: guidelines versus evidence
    Hilleman, Daniel E.
    CLINICAL LIPIDOLOGY, 2013, 8 (03) : 269 - 272
  • [33] Lipid-altering gene variants and cardiovascular risk in the older population
    Joy, Tisha R.
    Hegele, Robert A.
    CLINICAL LIPIDOLOGY, 2009, 4 (06) : 721 - 724
  • [34] Lipid-altering Efficacy of Ezetimibe/Simvastatin Compared with Rosuvastatin in Hypercholesterolaemic Patients: A Meta-Analysis
    Liu, Yongming
    Xia, Nan
    Hu, Wanying
    Zhao, Wei
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2019, 15 (02) : 200 - 208
  • [35] Colesevelam HCl: a non-systemic lipid-altering drug
    Bays, H
    Dujovne, C
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) : 779 - 790
  • [36] LIPID AND PLEIOTROPIC EFFECTS OF ATORVASTATIN IN HYPERTENSIVE DIABETIC AND NON-DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE
    Koshelskaya, O.
    Sushkova, A.
    Souslova, T.
    JOURNAL OF HYPERTENSION, 2009, 27 : S84 - S84
  • [37] Lipid-altering efficacy and tolerability of ER niacin/laropiprant in type 2 diabetes mellitus patients
    Maclean, A.
    Mckenney, J.
    Scott, R.
    Brinton, E.
    Bays, H.
    Giezek, H.
    Ruck, R.
    Gibson, K.
    Sisk, C. Mccrary
    Maccubbin, D.
    EUROPEAN HEART JOURNAL, 2009, 30 : 298 - 298
  • [38] Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies
    Rosenson, Robert S.
    Pitt, Bertram
    NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2009, 6 (02): : 98 - 100
  • [39] Beeswax policosanol failed to demonstrate lipid-altering effects in well-controlled clinical trials
    Lukashevich, Valentina
    Davidson, Michael H.
    Moreines, Judith
    Berlin, Roger G.
    CIRCULATION, 2006, 114 (18) : 892 - 892
  • [40] Lipid-altering efficacy of extended-release niacin/laropiprant in dyslipidaemic patients with metabolic syndrome
    Bays, H. E.
    Maccubbin, D. L.
    Shah, A. K.
    Lin, J.
    Sisk, C. M.
    Paolini, J. F.
    DIABETOLOGIA, 2008, 51 : S558 - S558